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Abstract
The recent approval of bevacizumab (Avastin), a humanized
anti–vascular endothelial growth factor (VEGF) monoclonal
antibody, in combination with chemotherapy for the treat-
ment of patients with metastatic colorectal cancer, has
provided proof of principle of the efficacy of antiangiogenic
strategies for cancer therapy. The activity of bevacizumab is
primarily attributed to its ability to inhibit endothelial cell
survival. Whether anti-VEGF strategies may also have a direct
effect on cancer cell survival is poorly understood. We show
that serum-starved colon cancer cells differentially respond to
autocrine production of VEGF with the induction of hypoxia
inducible factor-1A (HIF-1A) and survival under hypoxic
conditions. Inhibition of VEGF or VEGF receptor 2 (VEGFR2)/
KDR, but not VEGFR1/Flt-1, was sufficient to abrogate VEGF-
mediated induction of HIF-1A and survival in sensitive
HCT116, but not in resistant HT29, colon cancer cells. These
results provide evidence that a VEGF/KDR/HIF-1A autocrine
loop differentially mediates survival of hypoxic colon cancer
cells, and they suggest that colon cancer cells may be
intrinsically sensitive or resistant to anti-VEGF strategies,
which may determine the therapeutic efficacy of bevacizumab.
[Cancer Res 2008;68(1):285–91]
Introduction
Bevacizumab (Avastin), a humanized anti–vascular endothelial
growth factor (VEGF) monoclonal antibody, has been recently
approved for the treatment of patients with metastatic colorectal
cancer in combination with chemotherapy (5-fluorouracil, leuco-
vorin, and irinotecan), providing proof of principle that anti-
angiogenic strategies may be effective for the treatment of human
cancers (1). Addition of bevacizumab to chemotherapy increased
overall survival by f5 months in patients with metastatic
colorectal cancer (1). However, which patients may benefit from
treatment with bevacizumab is unclear (2). To explain the
increased therapeutic efficacy of combination strategies contain-
ing anti-VEGF antibodies, several hypotheses have been proposed,
including inhibition of new blood vessel formation or ‘‘normal-
ization’’ of the dysfunctional tumor vasculature (3, 4). Whether
anti-VEGF strategies may have a direct effect on cancer cell
survival is not known.
VEGF-A is a major angiogenic factor secreted under hypoxic
conditions by both cancer cells and stromal infiltrating cells (5).
VEGF-A binds to two tyrosine kinase receptors on endothelial cells:
VEGF receptor-1 (VEGFR1/Flt-1), whose function remains poorly
defined, and VEGFR2 (KDR), which mediates proliferation and
survival of endothelial cell (6). Expression of VEGFRs has also been
shown in nonendothelial cells, including hematopoietic stem cells
and monocytes, and more recently in a variety of tumor types (7, 8).
However, the function of VEGFRs on cancer cells is poorly
understood. Expression of Flt-1 in colon cancer cells has been
recently associated with induction of cell motility and invasion (9).
In contrast, the expression and function of KDR in colon cancer
cells, if any, has not been shown.
Most solid tumors develop regions of low oxygen tension
because of a tissue imbalance between oxygen supply and
consumption (10). Hypoxic cancer cells are more invasive and
metastatic, resistant to apoptosis and ultimately to chemotherapy
and radiation therapy (11). Hypoxia inducible factor 1 (HIF-1), a
master regulator of the hypoxic response in mammalian cells, may
act as a survival factor for cancer cells by inducing the expression
of genes that mediate angiogenesis, including but not limited to
VEGF-A, tumor metabolism, and metastasis (12). Failure to
eliminate the hypoxic fraction of solid tumors is eventually
associated with poor prognosis. Hence, the identification of
survival pathways used by hypoxic cancer cells is important for
the potential therapeutic implications, and strategies to target
hypoxic cell signaling are being actively pursued (13).
We show that colon cancer cells differentially express a functional
VEGF/KDR/HIF-1a autocrine loop that mediates survival under
hypoxic conditions. Importantly, bevacizumab induced apoptosis of
hypoxic HCT116 cells, which express a functional KDR but not
HT29. These results show that (a) VEGF mediates survival of
hypoxic HCT116 colon cancer cells in a HIF-1a–dependent fashion,
(b) colon cancer cells can differentially express a functional KDR
receptor, and (c) the presence of a functional response to VEGFmay
be associated with, and potentially predict for, efficacy of anti-VEGF
therapies in colon cancer patients.
Materials and Methods
Cell culture and reagents. HT29 and HCT116 cells were maintained in
RPMI containing 5% fetal bovine serum (FBS; Cambrex BioScience), and 2
mmol/L glutamine at 37jC in a humidified incubator containing 21% O2,
5% CO2 in air (called normoxia). Experiments under hypoxic conditions
(1% O2) were performed in the hypoxic workstation Invivo2 400 (Biotrace
International). Neutralizing antibodies against human insulin-like growth
factor (IGF-I), VEGF, basic fibroblast growth factor (bFGF), platelet-derived
growth factor-BB (PDGF-BB), and EGF and human recombinant VEGF-A
were purchased from R&D Systems.
Flow cytometry analysis. To evaluate cell surface expression of
VEGFR2/KDR, cells were stained with specific PE-conjugated antibodies
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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(R&D Systems) in 0.5% of bovine serum albumin for 1 h at 4jC, washed, and
immediately analyzed by flow cytometry (FACScan, Becton Dickinson).
Samples were gated on a dot plot showing forward scatter and side scatter
to exclude cell debris not within normal cell size. Gated cells were plotted
on a histogram plot, showing the background staining overlay with the
sample staining. Annexin V staining was performed using the Annexin V
FITC apoptosis kit (BD Bioscience) according to the manufacturer’s
instructions. Gated cells were plotted on a dot plot showing Annexin V
staining and propidium iodide staining.
Immunoblotting and immunoprecipitation. Cells were lysed in
radioimmunoprecipitation assay buffer, and typically, 100-Ag protein was
separated in a 4% to 20% Tris-glycine gel (Invitrogen) and transferred on a
polyvinylidene difluoride membrane (Invitrogen), as previously described
(14). The following antibodies were used: anti–HIF-1a (BD Biosciences),
anti-NRP1, anti Flt-1, KDR, PLCg (Santa Cruz Biotechnology), h-actin
(Chemicon), phosphorylated extracellular signal-regulated kinase 1/2
(ERK1/2) and total ERK1/2 (Cell Signaling), and anti–phosphorylated
tyrosine (Upstate). VEGFR2/KDR was immunoprecipitated from 500 Ag of
cell lysates by incubation with 10 AL of anti-KDR antibody (Santa Cruz
Biotechnology) for 1.5 h at 4jC followed by addition of 20 AL protein A/G
agarose (Santa Cruz Biotechnology) overnight at 4jC. The mixture was
centrifuged at 12,000g for 20 min; pellet was mixed with 40 AL of
2 Laemmli buffer, boiled for 5 min, and subjected to SDS-PAGE and
Western blotting as previously described (14).
Transient transfection. Specific small interfering RNA (siRNA) oligo-
nucleotides targeting VEGF (ID 42868), Flt-1 (ID 190, 191), KDR (ID 121,122),
and neuropilin 1 (ID 114375) were obtained from Ambion. HT29 and
HCT116 were transfected using Oligofectamine (Invitrogen) according to
the manufacturer’s instruction. Briefly, siRNA complexes were added to
subconfluent cells and then incubated in serum-free condition for 4 h at
37jC. Medium was then changed to RPMI with 5% FBS, and cells were
incubated for an additional 48 h before treatment, as indicated.
Real-time PCR. Total cellular RNA was isolated using RNA minikit
(Qiagen). One microgram of total RNA was used to perform reverse
transcription–PCR using RT-PCR kit (PE Biosystems) according to the
manufacturer’s instruction. Real-time PCR was performed using an ABI-
Prism 7700 Sequence Detector (Applied Biosystems) as previously described
(15). Primers specific for KDR mRNA were obtained from Applied
Biosystems (sequences are available upon request). Detection of 18S rRNA,
used as internal control, was performed using premixed reagents from
Applied Biosystems.
VEGF ELISA. Total levels of VEGF-A protein were measured on cell-free
supernatant using human VEGF-A Quantikine ELISA kit (R&D Systems).
Results
VEGF differentially regulates hypoxic induction of HIF-1A
in colon cancer cells. To investigate the involvement, if any, of
autocrine production of growth factors in the hypoxic induction of
HIF-1a in cancer cells, we screened a panel of 30 different cancer
cell lines, corresponding to the most common tumor types. Cells
were cultured, in the absence of exogenous growth factors, under
normoxic or hypoxic conditions for 18 h, in the absence or
presence of neutralizing antibodies targeting growth factors that
are frequently dysregulated in human cancers, including EGF,
bFGF, IGF-I, PDGF, and VEGF. Interestingly, we found that distinct
growth factors were implicated in the hypoxic induction of HIF-1a
in different tumor types and within the same tissue type
(Supplementary Fig. S1 and data not shown), consistent with cell
type–specific genetic alterations and aberrant signaling pathways.
We focused our attention on colon cancer cell lines, in which we
found that anti-VEGF antibodies significantly inhibited hypoxic
induction of HIF-1a in HCT116, HCT-15, SW620, and HCC2998, but
not in HT29, COLO-205, and KM-12 (Fig. 1A ; and Supplementary
Fig. S1). The differential response of colon cancer cell lines to anti-
VEGF antibodies was of interest because bevacizumab is currently
used for the treatment of patients with metastatic colorectal
cancer. HIF-1a was expressed at low or undetectable levels in
normoxic HCT116 and HT29 and was not affected by addition of
anti-VEGF antibodies (data not shown). Neutralizing anti-VEGF
antibodies (Fig. 1A) or bevacizumab (Fig. 1B), but not antibodies
against EGF, bFGF, IGF-I, or PDGF, completely abrogated hypoxic
induction of HIF-1a protein in HCT116 cells, consistent with
autocrine production of VEGF in these cells. In contrast, neither
anti-VEGF antibodies (Fig. 1A) nor bevacizumab (Fig. 1B) had any
effect on HIF-1a accumulation in HT29. To confirm the induction
of VEGF protein by hypoxia, HCT116 and HT29 were cultured
under normoxic or hypoxic conditions, and the levels of VEGF
protein were measured by ELISA. Hypoxia induced 3-fold and
Figure 1. Anti-VEGF antibodies inhibit hypoxic
induction of HIF-1a in HCT116, but not HT29.
A, HCT116 and HT29 cells were serum-starved for
24 h. Cells were then incubated for an additional
18 h under normoxic (21% O2) or hypoxic (1% O2)
conditions in the absence or presence of the
indicated neutralizing antibodies: anti-EGF
(50 ng/mL), anti-bFGF (1 Ag/mL), anti-IGF-I
(10 Ag/mL), anti-PDGF-BB (100 ng/mL), and
anti-VEGF (50 ng/mL). HIF-1a protein accumulation
was assessed by immunoblotting. h-Actin is shown
as loading control. B, cells were cultured as
described above under normoxic or hypoxic
conditions in the absence or presence of increasing
concentrations of bevacizumab (Bev ), and levels
of HIF-1a and h-actin were assessed by Western
blot. C, cells were cultured as described above and
incubated under normoxic or hypoxic conditions for
18 h. Levels of VEGF protein in the supernatants
were measured by a commercially available
ELISA kit. D, cells were cultured as described
above in the absence or presence of the indicated
concentrations of recombinant VEGF for 18 h and
levels of HIF-1a and h-actin were assessed by
Western blot.
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5-fold higher levels of VEGF protein in HT29 and HCT116,
respectively, relative to normoxic cells (Fig. 1C). However, hypoxia
induced much higher levels of VEGF protein in HCT116 (1.8 ng/mL)
relative to HT29 (0.6 ng/mL) cells. To rule out the possibility that
lower levels of secreted VEGF might account for the lack of
response in HT29, cells were treated with increasing concentrations
of VEGF (up to 50 ng/mL) under normoxic conditions, and the
levels of HIF-1a protein were measured. VEGF induced HIF-1a
protein accumulation in a dose-dependent fashion in HCT116, but
not in HT29 (Fig. 1D).
To further validate the involvement of VEGF-A and to rule out
the possibility that intracellular (16, 17), rather than secreted, VEGF
may still be active in HT29, cells were transfected with siRNA
negative control (siNC) or targeting VEGF-A (siVEGF), and hypoxic
induction of HIF-1a was measured. siVEGF, but not siNC,
completely inhibited hypoxic induction of HIF-1a in HCT116, but
had no effect in HT29 (Fig. 2A), demonstrating that autocrine
production of secreted VEGF is involved in the hypoxic induction
of HIF-1a in HCT116, but not HT29, and revealing an intrinsic
differential responsiveness of colon cancer cells to VEGF.
KDR, but not Flt-1, mediates VEGF-dependent induction of
HIF-1A in HCT116, but not HT29, hypoxic cells. To address
which receptor was required for the VEGF-dependent autocrine
induction of HIF-1a in colon cancer cells, HCT116 and HT29 cells
were cultured under normoxic or hypoxic conditions in the absence
or presence of neutralizing antibodies against Flt-1 or KDR, and
HIF-1a levels were measured. Anti-KDR, but not anti–Flt-1,
antibodies completely abolished hypoxic induction of HIF-1a in
HCT116 cells (Fig. 2B), consistent with VEGF-dependent activation
of VEGFR2/KDR. In contrast, neither anti-KDR nor anti–Flt-1
antibodies affected hypoxic induction of HIF-1a in HT29 (Fig. 2B).
The expression, if any, of KDR in colon cancer cells is
controversial. Flow cytometry analysis revealed low, but detectable,
levels of KDR surface expression, relative to human endothelial cell,
in HCT116 and little, if any, in HT29 (Fig. 2C). Consistent with this
result, KDR mRNA, measured by real-time PCR, was present in
HCT116, but at significantly lower levels relative to human
umbilical vascular endothelial cell (HUVEC) and was barely
detectable in HT29 (Supplementary Fig. S2). To investigate KDR
functional activation, HCT116 and HT29 cells were treated under
normoxic conditions in the absence or presence of recombinant
human VEGF or under hypoxic conditions. KDR was immunopre-
cipitated and Western blot was performed with anti-phosphotyr-
osine antibodies. Both hypoxia and VEGF induced phosphorylation
of KDR, relative to untreated normoxic cells, in HCT116, but not
HT29, cells, consistent with the presence of a functional receptor in
HCT116 (Fig. 2D).
Next, HCT116 and HT29 were transiently transfected with either
siNC or targeting two distinct sequences of Flt-1 and KDR,
respectively, and hypoxic levels of HIF-1a were measured (Fig. 3A).
Levels of Flt-1 and KDR expression were decreased by >90% in
HCT116 transfected with the corresponding siRNA. Notably, siRNA
targeting KDR, but not Flt-1, completely inhibited hypoxic
induction of HIF-1a expression relative to siNC, consistent with
data obtained using anti-KDR antibodies. In contrast, neither
siRNA was able to affect HIF-1a expression in HT29 (Fig. 3B).
These results are consistent with low, yet functional, levels of KDR
expression in HCT116 cells, but not in HT29cells.
Neuropilin-1 is a component of KDR, which increases the affinity
of the receptor for VEGF in endothelial cells (18). We tested the
expression of neuropilin-1 in HCT116 and HT29 cells cultured
under normoxic or hypoxic conditions. Neuropilin-1 was expressed
at much higher levels in HCT116 relative to HT29 and was not
modulated by hypoxia (Fig. 3C). To test whether neuropilin-1 was
functionally involved in the autocrine induction of HIF-1a by
VEGF, HCT116 and HT29 cells were transiently transfected with
siNC or targeting neuropilin-1 (siNRP). siNRP significantly inhibited
hypoxic induction of HIF-1a expression in HCT116, but not HT29,
cells (Fig. 3D), consistent with the involvement of neuropilin in
KDR functional activation. Similar results were obtained with a
second siRNA targeting a distinct sequence of neuropilin-1 (data
not shown).
Figure 2. HCT116 cells, but not HT29,
express a functional KDR. A, HCT116 and
HT29 were transfected with siNC or siVEGF.
At 48 h after transfection, cells were
serum-starved for 24 h and incubated under
normoxic or hypoxic conditions for 16 h.
Levels of HIF-1a and h-actin were assessed
by Western blot. B, HCT116 and HT29 cells
were serum-starved for 24 h. Cells were then
incubated under normoxia or hypoxia in the
absence or presence of neutralizing
antibodies against Flt-1 (50 ng/mL) or KDR
(50 ng/mL), alone or in combination for 18 h.
HIF-1a protein accumulation was assessed
by immunoblotting. h-Actin is shown as
loading control. C, surface expression of
KDR in HUVEC, HCT116, and HT29 cells
cultured under normoxic conditions was
analyzed by flow cytometry using a specific
anti-human KDR antibody. Dark area, cells
stained with an isotype-matched control
antibody; white area, KDR-positive cells.
Data are from one representative experiment
of three performed. D, cells were cultured
under normoxia in the absence or presence
of recombinant VEGF (50 nmol/L) for 15 min
or under hypoxic conditions for 18 h. Cell
lysates were immunoprecipitated with
anti-KDR antibodies, and immunoblotting
was performed using anti-KDR or
anti-phosphorylated Tyr antibodies.
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Autocrine production of VEGF mediates survival of HCT116,
but not HT29, cells under hypoxic conditions. As hypoxic
cancer cells may be resistant to apoptosis, we hypothesized that
VEGF might be involved in mediating survival of hypoxic colon
cancer cells expressing a functional KDR. HCT116 and HT29 were
cultured under normoxic or hypoxic conditions in the absence or
presence of either bevacizumab or control IgG, and the percentage
of apoptotic cells was measured by Annexin V staining. A lower
percentage of apoptotic HCT116 cells was observed under hypoxic
relative to normoxic conditions (19% versus 30%; Fig. 4A),
consistent with hypoxia-dependent autocrine production of
survival factor(s) and the previously reported induction of apop-
tosis in HCT116 after serum withdrawal (19). Addition of bevaci-
zumab, but not a control IgG, increased the number of hypoxic
apoptotic cells to 29%, comparable with levels observed in
normoxic cells (30%). More importantly, anti-KDR, but not anti–
Flt-1, antibodies increased the percentage of apoptotic cells from
21%, in the presence of a control IgG, to 35% (Fig. 4A). These
results show that the effects of VEGF on survival of hypoxic
HCT116 cells are mediated by KDR, and they suggest that other
VEGF isoforms, which are not neutralized by bevacizumab, may
contribute to survival of hypoxic HCT116 by a KDR-dependent
mechanism (20). In contrast, slightly higher levels of apoptosis were
detected in HT29 cultured under hypoxic relative to normoxic
conditions (18% versus 12%), and none of the antibodies used
affected survival of hypoxic HT29 cells (Fig. 4A).
To further validate the involvement of a VEGF/KDR autocrine
loop in the survival of hypoxic cells, HCT116 were transiently
transfected with siNC or siVEGF, Flt-1 (siFlt-1), or KDR (siKDR),
respectively. As shown in Fig. 4B , siVEGF increased apoptosis of
hypoxic cells to 34%, relative to 14% in the presence of siNC. In
addition, siKDR consistently increased the percentage of apoptotic
cells from 14% (siNC) to 44% and 50%, respectively, using two
siRNA targeting distinct sequences (Fig. 4B). In contrast, two
distinct siRNA targeting Flt-1 had no effect on survival of hypoxic
HCT116 cells and neither siRNA had any effect on survival of HT29
(Fig. 4B). Anti-VEGF antibodies, siVEGF, or siKDR also increased
the levels of poly(ADP-ribose) polymerase (PARP) cleavage in
hypoxic HCT116, relative to control IgG or siNC, providing further
evidence of induction of apoptosis under these conditions (data
not shown). To address if HIF-1a was involved in the VEGF-
dependent survival effect, HCT116 and HT29 cells were transfected
with siNC or siRNA targeting HIF-1a and cultured under normoxic
or hypoxic conditions. siRNA targeting HIF-1a increased the
percentage of apoptosis in hypoxic HCT116, but not HT29, cells to
24%, relative to 4.5% in the presence of siNC (Fig. 4C).
Overall, these data show that VEGF and HIF-1a mediate survival
of hypoxic colon cancer cells, and they suggest that colon cancer
cells may be differentially sensitive to induction of apoptosis upon
inhibition of VEGF activity.
VEGF mediates survival of HCT116 cells via a PLC;/ERK-
dependent pathway. PLCg is phosphorylated in a KDR-dependent
fashion and may activate the ras/raf pathway in endothelial cells
(21, 22). To test whether PLCg was activated under our
experimental conditions, HCT116 cells were cultured under
normoxic or hypoxic conditions in the absence or presence of
neutralizing antibodies targeting VEGF, KDR, or Flt-1 and tyrosine
phosphorylation of PLCg was measured in cell lysates. Hypoxia
Figure 3. KDR mediates autocrine induction of HIF-1a
by VEGF in HCT116, but not HT29, cells. A and B,
HCT116 (A ) or HT29 (B ) cells were transfected with
siNC or targeting two distinct regions of Flt-1 (siFlt1#A
and siFlt1#B) or KDR (siKDR#A and siKDR#B),
respectively. At 48 h after transfection, cells were
serum-starved for 24 h and then incubated under
hypoxia for 18 h. Normoxic nontransfected cells
(lane 1 ). Levels of HIF-1a, Flt-1, and KDR were
measured by Western blot. h-Actin is shown as loading
control. C, HCT116 and HT29 were serum-starved
and then were incubated under normoxic or hypoxic
conditions for 18 h, and levels of neuropilin 1 (NRP-1 )
were assessed by immunoblotting. h-Actin is shown as
loading control. D, HCT116 and HT29 were transfected
with siNC or siNRP. At 48 h after transfection, cells
were serum-starved for 24 h and incubated under
hypoxia for 24 h. Normoxic nontransfected cells
(lane 1 ). Levels of HIF-1a and neuropilin 1 were
measured by Western blot. h-Actin is shown as loading
control.
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induced phosphorylation of PLCg in HCT116, relative to
normoxic cells, which was almost completely abrogated by
addition of neutralizing antibodies against either VEGF or KDR,
but not Flt-1, consistent with a functional VEGF/KDR pathway
(Fig. 5A). In contrast, PLCg phosphorylation was not detectable in
HT29 cells cultured under hypoxia or in the presence of VEGF
(data not shown).
Next, we tested the phosphorylation of ERK1/2 in HCT116 cells
cultured under normoxia or hypoxia in the absence or presence of
PLCg (U73122) or ERK (PD98059) inhibitors. We found that ERK
was activated under hypoxic conditions and was inhibited by both
PD98059 and U73122, indicating that ERK1/2 activation is
downstream of PLCg (Fig. 5B). Notably, inhibition of PLCg or
ERK1/2 also significantly affected hypoxic induction of HIF-1a,
suggesting that the same signaling pathways mediate survival and
HIF1a expression in HCT116 cells (Fig. 5C). Indeed, inhibition of
PLCg or ERK1/2 increased the number of apoptotic cells to 30%
and 58%, respectively, relative to hypoxic cells (12%; Fig. 5D).
Consistent with these results, PARP cleavage was observed in
normoxic but not in hypoxic HCT116 cells and was induced in
hypoxic cells treated with U73122 or PD98059 (data not shown).
In summary, our data show that a VEGF/KDR/PLCg/ERK1/2
pathway is activated by hypoxic HCT116 cells to induce HIF-1a
expression and survival under hypoxic stress conditions.
Figure 4. Autocrine secretion of VEGF mediates KDR-dependent survival of HCT116, but not HT29, cells. A, HCT116 and HT29 cells were serum-starved in RPMI
for 24 h. Cells were then incubated under normoxia or hypoxia in the absence or presence of bevacizumab or neutralizing antibodies against Flt-1 or KDR or
isotype-matched IgG for 24 h. Percentage of apoptotic cells was measured by flow cytometry analysis of Annexin V versus propidium iodide–positive cells. Percentage
of Annexin V-positive cells (bottom, propidium iodide–negative; top, propidium iodide–positive) from one representative experiment. B, HCT116 and HT29 cells
were either nontransfected or transfected with siNC, siVEGF, Flt-1 (siFlt-1#A and siFlt-1#B) or KDR (siKDR#A and siKDR#B). At 48 h after transfection, cells were
serum-starved for 24 h and then incubated under normoxic or hypoxic conditions for an additional 24 h. Apoptosis was measured by Annexin V staining. Percentage of
Annexin V–positive cells from one representative experiment. C, HCT116 and HT29 cells were transfected as described above with siNC or siRNA targeting HIF-1a
(siHIF-1a ) and incubated under hypoxia for 24 h. Normoxic nontransfected cells are also shown.
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Discussion
We recently identified an autocrine survival loop involving FGF-2
and HIF-1a in hypoxic human endothelial cells (14). By culturing
colon cancer cells under hypoxic conditions in the absence of
exogenous growth factors, which mimics nutrient and oxygen
deprivation found in solid tumors, we have discovered that anti–
VEGF-A antibodies, including bevacizumab, significantly inhibited
hypoxic induction of HIF-1a in HCT116, HCT15, SW620, and
HCC2998, but not in HT29, KM12, and COLO205. More importantly,
inhibition of VEGF or VEGF signaling blocked survival of hypoxic
HCT116, but not HT29, cells. These results are consistent with (a)
the potential involvement of VEGF in mediating survival of hypoxic
colon cancer cells and (b) a differential responsiveness of hypoxic
colon cancer cells to VEGF and its inhibition.
The involvement of VEGF in mediating survival of hypoxic colon
cancer cells was surprising because VEGF is thought to be
primarily a survival factor for endothelial cells (23). Recently,
however, evidence has been provided that VEGF may also act on
cancer cells that express receptors for VEGF, including Flt-1, KDR,
and flt-4 (7, 8, 24). In nonendothelial cells, Flt-1 has been shown to
mediate migration of human monocytes and, more recently, cell
motility and invasion of colon cancer cells lines (9). The expression
and function of KDR has been shown in hematopoietic stem cells
and in hematologic malignancies (7, 8). However, the functional
role of KDR, if any, in solid tumors remains elusive. We found that
anti-KDR antibodies or siRNA targeting KDR, but not Flt-1,
significantly inhibited hypoxic induction of HIF-1a and survival
in HCT116, but not HT29. These results raised the possibility that
HCT116 expressed a functional KDR receptor. Analysis of the
expression and function of KDR in HCT116 and HT29 cells was
overall consistent with low, yet functional, levels of KDR in
HCT1116, but not HT29. Accordingly, phosphorylation of KDR, an
indication of its functional activation, was only detectable in
HCT116 and not in HT29.
The relatively low, yet functional, levels of KDR expression in
HCT116 is consistent with two possibilities: the first is that very low
levels of KDR surface receptor are expressed on the majority of
cells, which would account for the response of HCT116 cells to
anti-VEGF antibodies; alternatively, only a subset of cells expresses
a functional receptor and is sensitive to VEGF inhibition, which is
more consistent with the pattern of KDR surface expression that
we observed. Conversely, the presence of an autocrine survival loop
in a subset of cells expressing a functional KDR would render them
more resistant to chemotherapy-induced apoptosis under hypoxic
stressed conditions, which may contribute to treatment failure.
Interestingly, expression of VEGFR(s) has been shown in stem cell–
like populations, and evidence has been provided that hypoxia may
be a favorable environmental condition for the maintenance of the
stem cell phenotype (25, 26).
The lack of a functional VEGF/KDR signaling pathway in HT29
may confer intrinsic resistance to anti-VEGF therapies. The
possibility that intracellular, rather than secreted, VEGF might
be signaling in HT29 was ruled out by using siRNA targeting
VEGF or KDR, which failed to show any effect on hypoxic
induction of HIF-1a or survival in HT29. It is possible that the
overall low levels of expression of both ligand (VEGF) and
receptor (KDR) or coreceptor, e.g., neuropilin, in HT29 might
account for the lack of functional activity. Neuropilin-1, a
coreceptor of KDR that increases the affinity for VEGF, is
expressed in both endothelial cells and cancer cell lines (27, 28)
and plays a crucial role in VEGF signaling. Indeed, we found that
neuropilin-1 was expressed at higher levels in HCT116, relative to
HT29, and was functionally implicated in the hypoxic induction of
HIF-1a in HCT116.
HIF-1a may act as a survival factor in a tumor type–specific
fashion, and strategies to inhibit HIF are being developed (13). Our
data indicate that PLCg and ERK1/2 are involved in VEGF-
dependent induction of HIF-1a and survival of hypoxic HCT116
Figure 5. A PLCg-dependent pathway mediates autocrine induction of HIF-1a and survival by VEGF. A, HCT116 cells were serum-starved for 24 h. Cells were
then cultured under normoxic or hypoxic conditions in the absence or presence of neutralizing antibodies against Flt-1, KDR or VEGF for 18 h. Cell lysates were
immunoprecipitated with anti-PLCg antibodies, and immunoblotting was performed with anti-PLCg or anti–phosphorylated tyrosine antibodies. B, HCT116 cells were
cultured as described above under normoxic or hypoxic conditions in the absence or presence of inhibitors of PLCg (U73122, 10 Amol/L) or ERK (PD98059, 50 Amol/L)
for 24 h. Levels of total and phosphorylated ERK were measured by immunoblotting. C, HCT116 cells were cultured as above in the absence or presence of
U73122 or PD98059 under normoxic or hypoxic conditions for 18 h. Levels of HIF-1a were measured by Western blot. h-Actin is shown as loading control. D, HCT116
cells were cultured under normoxic or hypoxic conditions in the absence or presence of inhibitors of PLCg (U73122, 10 Amol/L) or mitogen-activated protein kinase
(PD98059, 50 Amol/L), and apoptosis was measured by Annexin V staining. Percentage of Annexin V–positive cells from one representative experiment.
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cells. PLCg is phosphorylated in a KDR-dependent fashion and may
activate the ras/raf pathway in endothelial cells (21, 22). Consistent
with this observation, we found that ERK1/2 was phosphorylated
in a PLCg-dependent fashion in hypoxic HCT116 cells and was
required for both HIF-1a expression and cell survival. These results
indicate that PLCg may represent a novel target for the inhibition
of survival of hypoxic colon cancer cells, and they suggest that
small molecules targeting signaling pathways frequently dysregu-
lated in human cancers may effectively block HIF-1a and survival
of hypoxic cells in a cell type–specific fashion.
The recent approval of bevacizumab for the treatment of
metastatic colorectal cancer in combination with chemotherapy
has provided evidence that antiangiogenic strategies may be
effective in human cancers and has generated enthusiasm for their
clinical application. However, the exact mechanism by which
bevacizumab increases the efficacy of chemotherapy remains
poorly understood. Mechanisms implicating inhibition of new
blood vessel formation, normalization of existing vasculature, or
inhibition of circulating endothelial precursor cells have been
suggested (3, 4). However, a direct effect of anti-VEGF antibodies on
survival of colon cancer cells has not been implicated. Our results
show that colon cancer cells may be intrinsically vulnerable or
resistant to VEGF inhibition. Taking HCT116 and HT29 as
paradigms of distinct functional phenotypes of colon cancer cells,
we speculate that efficacy of anti-VEGF therapies may be, at least in
part, determined by the intrinsic sensitivity of colon cancer cells to
inhibition of VEGF-dependent survival pathways. Interestingly, we
found that addition of bevacizumab to 5-fluorouracil increases the
percentage of apoptotic cells in VEGF-sensitive (HCT116) but not
resistant (HT29) colon cancer cells (data not shown). The limited
survival benefit of colorectal cancer patients treated with
bevacizumab suggests that only a subset may benefit from the
addition of anti-VEGF antibodies to conventional chemotherapy.
Ongoing efforts to identify predictive biomarkers of response to
anti-VEGF therapies are predominantly, if not exclusively, focused
on endothelial cells and the vasculature of solid tumors. Our results
suggest that, in addition to the effect on endothelial cells, the
intrinsic sensitivity or resistance of hypoxic cancer cells to VEGF
inhibition may contribute to the efficacy of anti-VEGF therapies for
human cancers.
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